| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 41 | QUANTITATIVE MULTIPLEX DETECTION OF PATHOGEN BIOMARKERS | US14317378 | 2014-06-27 | US20140370532A1 | 2014-12-18 | Harshini Mukundan; Hongzhi Xie; Basil I. Swanson; Jennifer Martinez; Wynne K. Grace |
| The present invention addresses the simultaneous detection and quantitative measurement of multiple biomolecules, e.g., pathogen biomarkers through either a sandwich assay approach or a lipid insertion approach. The invention can further employ a multichannel, structure with multi-sensor elements per channel. | ||||||
| 42 | TARGET CAPTURE SYSTEM | US14107315 | 2013-12-16 | US20140170652A1 | 2014-06-19 | Ravil A. Sitdikov; Eddie W. Adams; Magdalena A. Torrance; David K. Aley; Erik J. Smith; Victor C. Esch |
| The invention generally relates to a system for isolating or separating a target from a sample. In certain aspects, processes performed by the target capture system include introducing a plurality of magnetic particles, in which a plurality of the particles include at least one binding moiety specific to a target, into a sample to form at least one target/particle complex and applying a magnetic field to isolate the magnetic particle/target complexes from the sample. The process starts at inputting a sample into the system and ends at delivering a capture target or nucleic acids of the target into a container for further analysis. | ||||||
| 43 | Detection of Mycobacterium Tuberculosis Bacilli | US12816106 | 2010-06-15 | US20100317037A1 | 2010-12-16 | Ahmad Bahrmand |
| A screening test for Mycobacterium tuberculosis in patient samples includes an antibody preparation prepared against the cell wall antigens of M. tuberculosis. One embodiment of the screening test is rapid and has a negative predictive value of 95% or more. Furthermore, the use of an antibody preparation that will specifically bind to multidrug resistant strains of Mycobacterium tuberculosis bacilli permits the screening test to differentiate the detection of Mycobacterium tuberculosis bacilli strains that are resistant to the antibiotics rifampicin and isoniazid. | ||||||
| 44 | EXTRACELLULAR MATRIX-BINDING PROTEINS FROM STAPHYLOCOCCUS AUREUS | US12546289 | 2009-08-24 | US20100081616A1 | 2010-04-01 | Joseph M. Patti; Timothy J. Foster; Elisabet Josefsson; Deidre Ni Eidhin; Magnus A.O. Hook; Samuel E. Perkins |
| An isolated extracellular matrix-binding protein, designated as SdrD and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. | ||||||
| 45 | Anthrax carbohydrates, synthesis and uses thereof | US12317693 | 2008-12-24 | US20090246200A1 | 2009-10-01 | Russell W. Carlson; Geert-Jan Boons; Therese Buskas; Biswa Choudhury; Elmar Kannenberg; Christine Leoff; Alok Mehta; Elke Saile; Jana Rauvolfova; Conrad Quinn; Patricia Wilkins; Mahalakshmi Vasan; Margreet A. Wolfert |
| The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies. | ||||||
| 46 | DNA encoding Toxoplasma gondii rDGP5p protein | US11701872 | 2007-02-02 | US07544789B1 | 2009-06-09 | Dolores E. Hill; Dante S. Zarlenga; Cathleen Coss; Jitender P. Dubey |
| Recombinant proteins have been developed for the detection of Toxoplasma gondii oocyst proteins for example in biological fluids. Isolated DNA sequences which encode these proteins have also been developed. The DNA sequences may be inserted into recombinant DNA molecules such as cloning vectors or expression vectors for the transformation of cells and the production of the proteins. | ||||||
| 47 | METHOD FOR DETECTING COLIFORM BACTERIA CONTAINED IN MILK | EP14870998 | 2014-12-17 | EP3085769A4 | 2017-07-19 | MAEHANA KOJI; MATSUYAMA KENJI |
| The object is to provide a lysis method, lysis treatment solution, detection method using an immunochromatographic device, and detection kit comprising an immunochromatographic device for detecting whether causative bacteria of mastitis are coliform bacteria or not by using milk of a livestock animal. There is provided a method for lysing coliform bacteria, which comprises the step of mixing a lysis agent containing a lytic enzyme, and at least one kind of anionic surfactant, and preferably further containing at least one kind of nonionic surfactant, with milk obtained form a livestock animal to lyse coliform bacteria existing in the milk. The lytic enzyme is preferably lysozyme. | ||||||
| 48 | RISK STRATIFICATION IN INFLUENZA | EP13817599 | 2013-07-10 | EP2872891A4 | 2016-01-20 | MCLEAN ANTHONY; TANG BENJAMIN; PARNELL GRANT PETER; SHOJAEI MARYAM |
| The present invention relates to methods for the identification of clinical risk in patients having, or suspected of having, influenza. The invention also relates to methods for distinguishing between patients having influenza or viral pneumonia from patients having a symptomatically similar condition. The methods of the invention comprise determination of the level of expression of interferon alpha inducible protein 27 (IF127) in a biological sample from a patient having, or suspected of having, influenza. Kits comprising suitable components for the performance of the methods are also provided by the invention. The invention allows stratification of patients into groups defining clinical risk, for example groups based on the severity of risk to the long-term health of the subject. | ||||||
| 49 | ANTIBODIES DIRECTED AGAINST INFLUENZA | EP12841118 | 2012-10-18 | EP2768858A4 | 2015-06-03 | AHMED RAFI; WRAMMERT JENS; WILSON PATRICK C |
| Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided. | ||||||
| 50 | METHOD AND APPARATUS FOR SELECTIVE BIOLOGICAL MATERIAL DETECTION | EP01941459.8 | 2001-04-16 | EP1290445A2 | 2003-03-12 | BODENHAMER, William, T. |
| The present invention relates to bioassay materials useful for the detection of toxic substances and, more particularly, to packaging materials for food and other products, along with methods for their manufacture and use. The invention provides a unique composite material capable of detecting and identifying multiple biological materials within a single package. The biological material identification system is designed for incorporation into existing types of flexible packaging material such as polyvinylchloride or polyolefin films, and its introduction into the existing packaging infrastructure will require little or no change to present systems or procedures. | ||||||
| 51 | Diagnosis and treatment of bacterial dysentery | EP00101263.2 | 1992-10-19 | EP1018342A2 | 2000-07-12 | Armstrong, Glen D.; Ratcliffe, R. Murray |
There is provided the use of an agent in the preparation of a medicament for the prevention or treatment of an enteric infection mediated by an SLT, wherein said agent is a pharmaceutically acceptable solid inert affinity support capable of being eliminated from the gastrointestinal tract, which support has an affinity ligand covalently attached thereto through a spacer arm, wherein said ligand is characterized as an oligosaccharide containing the disaccharide subunit αGal(1-4)βGal which binds the SLT; |
||||||
| 52 | FORMULATIONS OF RECOMBINANT PAPILLOMAVIRUS VACCINES | EP97952496.0 | 1997-12-16 | EP0957936A1 | 1999-11-24 | GUPTA, Sunil, K.; MARK, George, E., III |
| Vaccine formulations comprising recombinant early (E) and late (L) proteins of papillomavirus and oxidized mannan as well as methods of making and using the formulations are provided. | ||||||
| 53 | DIAGNOSIS AND TREATMENT OF BACTERIAL DYSENTERY | EP92922817.0 | 1992-10-19 | EP0610356A1 | 1994-08-17 | ARMSTRONG, Glen, D.; RATCLIFFE, R., Murray |
| There is provided the use of an agent in the preparation of a medicament for the prevention or treatment of an enteric infection mediated by an SLT, wherein said agent is a pharmaceutically acceptable solid inert affinity support capable of being eliminated from the gastrointestinal tract, which support has an affinity ligand covalently attached thereto through a spacer arm, wherein said ligand is characterized as an oligosaccharide containing the disaccharide subunit alpha Gal(1-4) beta Gal which binds the SLT; with the proviso that the disaccharide is not part of a alpha Gal(1-4) beta Gal(1-4) beta GlcNAc trisaccharide or a alpha Gal(1-4) beta Gal(1-4) beta Glc trisaccharide. | ||||||
| 54 | 마이코플라즈마 뉴모니아의 면역학적 검출법 및 키트 | KR1020177022810 | 2016-01-27 | KR1020170106407A | 2017-09-20 | 사이토켄지 |
| (과제) 본발명은마이코플라즈마폐렴의원인균인마이코플라즈마뉴모니아를간편하며또한신속하게고감도검출을가능하게하는특이적항체, 또한상기항체를포함하는면역학적검출법및 키트를제공하는것을목적으로한다. (해결수단) 마이코플라즈마뉴모니아의 P30 단백질의특정에피토프를인식하는항체를제작하고, 상기항체를사용하여면역학적검출을행함으로써마이코플라즈마뉴모니아의감염을종래법보다신속하며또한특이적으로진단할수 있다. 본발명에의하면특수한기기및 숙련된기술을필요로하는일 없이병원등에있어서간편하며또한신속하게마이코플라즈마뉴모니아의검출및 감염을진단하는것이가능해진다. | ||||||
| 55 | 펩티도글리칸 결합단백질을 이용한 박테리아 검출용 프로브 및 그의 이용 | KR1020160043030 | 2016-04-07 | KR1020160120682A | 2016-10-18 | 정봉현; 임은경; 박경숙; 최종민 |
| 본발명은펩티도글리칸결합단백질을이용한박테리아검출용프로브및 이의제조방법에관한것이다. 또한, 본발명은상기프로브를이용하여박테리아를검출하는방법에관한것이다. 본발명에따른박테리아검출용프로브는박테리아를특이적으로검출할수 있다. 즉본 발명에따른상기프로브는효모와박테리아를명확히구분할수 있으며, 그람음성또는그람양성박테리아를모두검출할수 있는바, 범용적인박테리아검출용프로브로다방면에이용될수 있을것으로기대된다. 또한, 별도의효소의처리없이, 형광의발색여부만을확인하는것으로박테리아를검출할수 있는바, 간편하면서신속한박테리아의검출이가능하다. 특히, 신속한박테리아검출이요구되는식품업계에서효과적으로이용될수 있을것으로기대된다. | ||||||
| 56 | 인플루엔자에서의 위험도 계층화 | KR1020157003223 | 2013-07-10 | KR1020150040289A | 2015-04-14 | 맥클린,안토니; 탕,벤자민; 파르넬,그랜트,피터; 쇼자에이,마리암 |
| 본발명은인플루엔자를가지거나가지는것으로의심되는환자들내의임상적인위험도의확인을위한방법들에관한것이다. 본발명은또한인플루엔자또는바이러스성폐렴을가지는환자들과징후적으로유사한상태를가지는환자들을구별하기위한방법들에관한것이다. 본발명의방법들은인플루엔자를가지거나가지는것으로의심되는환자로부터의생물샘플내의인터페론알파유도단백질 27(IFI27)의발현의레벨의결정을포함한다. 상기방법들을수행하기위해적합한구성요소들을포함하는키트들도본 발명에서제공된다. 본발명은임상적인위험도를정의하는그룹들, 예를들면, 대상의장기간의건강에대한심각한위험도에기초한그룹들로환자들의계층화를가능하게한다. | ||||||
| 57 | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease | US15680629 | 2017-08-18 | US10130695B2 | 2018-11-20 | Kenya Honda; Bernat Olle; Koji Atarashi; Takeshi Tanoue; Hiroshi Ohno; Shinji Fukuda; Koji Hase |
| Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent. | ||||||
| 58 | Avian reovirus vaccines | US15223623 | 2016-07-29 | US09968671B2 | 2018-05-15 | Holly S. Sellers |
| The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses. | ||||||
| 59 | IMMUNOLOGICAL DETECTION METHOD AND KIT FOR MYCOPLASMA PNEUMONIAE | US15547346 | 2016-01-27 | US20180009880A1 | 2018-01-11 | Kenji SAITO |
| The present invention aims at providing a specific antibody that can simply and rapidly detect Mycoplasma pneumoniae which is a causative bacterium of mycoplasma pneumonia, with high sensitivity, and also an immunological detection method and a kit containing the same antibody. The present invention makes it possible to diagnose infection with Mycoplasma pneumoniae more rapidly and specifically than the conventional method, by producing an antibody recognizing a specific epitope of P30 protein of Mycoplasma pneumoniae and performing an immunological detection using the antibody. Also, the present invention enables easy and rapid detection of Mycoplasma pneumoniae and diagnosis of infection with the same at a hospital or the like without need of specialized instruments or skilled techniques. | ||||||
| 60 | Eukaryotic Cells with Artificial Endosymbionts for Multimodal Detection | US15709908 | 2017-09-20 | US20180008728A1 | 2018-01-11 | Caleb B. Bell, III; Alexey Bazarov |
| The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. | ||||||
QQ群二维码
意见反馈
意见反馈